Navigation Links
Global Intravenous (IV) Iron Drugs Industry
Date:6/1/2011

NEW YORK, June 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Intravenous (IV) Iron Drugs Industry

http://www.reportlinker.com/p0305172/Global-Intravenous-IV-Iron-Drugs-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 18 companies including many key and niche players such as AMAG Pharmaceuticals, Inc., Fresenius Medical Care AG & Co. KGaA, Galenica Ltd., Vifor Pharma Ltd., Luitpold Pharmaceuticals, Inc., American Regent, Inc., Pharmacosmos A/S, Rockwell Medical Technologies, Inc., Sanofi-Aventis U.S. LLC, Syner-Med (Pharmaceutical Products) Ltd., and Watson Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

INTRAVENOUS (IV) IRON DRUGS MCP-6464

A GLOBAL MARKET REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

A Quick Primer II-1

Current and Future Analysis II-1

United States - The Largest Market for IV Iron Drugs II-1

Europe and Rest of World - High Potential Markets II-2

Noteworthy Trends in the IV Iron Drug Market II-2

No Impact of Recession on Intravenous Iron Market II-2

Dialysis Clinics are Major Clients for IV Iron Supplements II-2

Global Iron Supplement Market II-2

Table 1: Global Intravenous (IV) Iron Market (2006):

Percentage Breakdown of Value Sales for Intravenous Iron Drug

Type - Non Generics and Generics II-3

Table 2: Leading Players in the Global Intravenous (IV) Iron

Market (2006): Percentage Breakdown of Value Sales for Vifor,

Sanofi-Aventis, Pharmacosmos, and Others (including Generics)

(includes corresponding Graph/Chart) II-3

Vifor Pharma - Dominates IV Iron Drugs Market II-3

2. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS II-4

Significance of Iron in Human Body II-4

Intravenous Therapy II-4

Iron-Deficiency Anemia II-4

People with High Susceptibility to Anemia II-4

Older Adults & the Elderly II-5

Cancer Patients II-5

Women of Child-bearing Age II-5

Chronic Kidney Disease Patients II-5

HIV/AIDS Patients II-5

People with Inflammatory Bowel Disease II-5

Diabetics II-6

People with Heart Disease II-6

Critically Ill Patients II-6

Infants II-6

People with Other Diseases II-6

Table 3: Intravenous (IV) Iron Drugs Market (2009):

Prevalence of Iron Deficiency Disease (IDA) by Risk Groups-

Pregnant Women, Children (1-2 years), Women (12-49

years), Women (50+ years), and Men (12+ years) (includes

corresponding Graph/Chart) II-6

Treatment for Iron Deficiency Anemia II-7

Iron Requirement in Chronic Kidney Disease II-7

Classification of Iron Deficiency in CKD II-7

Treating Iron Deficiency in CKD Patients II-7

Side Effects of Iron Supplementation in CKD II-8

Methods of Restoring Iron II-8

Oral Iron Therapy II-9

IV Iron-Infusion Therapy II-9

Intravenous (IV) Iron II-9

Conditions for Receiving Iron Injections II-10

Injection Procedure II-11

Categories of Iron Injections II-11

Ferumoxytol II-11

Iron Dextran II-12

Carbohydrate Iron II-12

Suitability of IV Iron Preparation II-12

Suitability of Regimen II-13

Management of Iron Doses II-13

Effectiveness of Iron Injection II-14

Requirement of Test Dose II-14

Side Effects of Iron Injections II-15

Iron Therapy: Caution II-15

Relevance of Iron Infusion Time II-15

Iron Overdose II-15

Iron-Out-of-Balance Therapies II-16

Blood Donation II-16

Therapeutic Phlebotomy II-16

Red Cell Apheresis II-16

Iron Chelation Therapy II-16

Iron-Chelating Drugs II-17

Desferrioxamine or Desferal II-17

Deferiprone or Ferriprox II-17

Conditions for Undergoing Iron Chelation Therapy II-17

Kinds of Chelation Therapy II-18

Side Effects Caused by IV Iron Chelation II-18

Conclusion II-19

3. SELECT IV IRON DRUGS PRESCRIBED FOR IRON DEFICIENCY II-20

Iron Sucrose (Venofer®) II-20

Iron dextran (InFed®, Dexferrum®) II-20

Sodium Ferric Gluconate (Ferrlecit®) II-21

Ferumoxytol (FerahemeTM) II-21

Ferric Carboxymaltose (Ferinject®, Injectafer®) II-22

4. SOLUBLE FERRIC PYROPHOSPHATE (SFP): A PIPELINE DRUG II-23

5. CLINICAL TRIALS II-24

Rockwell Medical Technologies Presents Positive Clinical Data

on Phase IIb Study of SFP II-24

FAIR-HF Study Meets Primary Endpoints in Treating Iron

Deficiency and Chronic Heart Failure II-25

6. PRODUCT LAUNCHES/APPROVALS II-26

AMAG Pharmaceuticals Launches Feraheme™ in the US II-26

Feraheme™ Receives FDA Approval for Intravenous Iron Therapy

in Adult CKD Patients II-26

Syner-Med Unveils Ferinject® in the UK II-27

Galencia Receives Approval in EU for Ferinject II-27

7. RECENT INDUSTRY ACTIVITY II-28

AMAG Pharmaceuticals Inks Agreement with Takeda Pharmaceutical

Company for Feraheme® II-28

Pharmacosmos Bags Marketing Authorizations for Monofer® II-28

Pharmacosmos Launches New Subsidiary II-28

Watson Pharmaceuticals Inks License Agreement with GeneraMedix II-29

Dabur Pharma Gets A New Name II-29

AMAG Pharmaceuticals Inks Agreement with 3SBio II-29

Fresenius Kabi Acquires Dabur Pharma II-30

Fresenius Medical Care Inks License Agreement with Luitpold

Pharmaceuticals and American Regent II-30

Fresenius Medical Care Inks Licensing Agreements for IV Iron

Products II-31

8. FOCUS ON SELECT GLOBAL PLAYERS II-32

AMAG Pharmaceuticals, Inc. (US) II-32

Fresenius Medical Care AG & Co. KGaA (Germany) II-32

Galenica Ltd. (Switzerland) II-32

Vifor Pharma Ltd. (Switzerland) II-32

Luitpold Pharmaceuticals, Inc. (US) II-33

American Regent, Inc. (US) II-33

Pharmacosmos A/S (Denmark) II-34

Rockwell Medical Technologies, Inc. (US) II-34

Sanofi-Aventis U.S. LLC (US) II-34

Syner-Med (Pharmaceutical Products) Ltd. (UK) II-34

Watson Pharmaceuticals, Inc. (US) II-35

9. GLOBAL MARKET PERSPECTIVE II-36

Table 4: World Recent Past, Current and Future Analysis for

Intravenous (IV) Iron Drugs by Geographic Region - US, Europe,

and Rest of World Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) II-36

Table 5: World Historic Review for Intravenous (IV) Iron Drugs

by Geographic Region - US, Europe, and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2001 through 2006 (includes corresponding

Graph/Chart) II-37

Table 6: World 13-Year Perspective for Intravenous (IV) Iron

Drugs by Geographic Region - Percentage Breakdown of Dollar

Sales for US, Europe, and Rest of World Markets for Years

2003, 2009 and 2015 (includes corresponding Graph/Chart) II-38

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Outlook III-1

CKD Revs up Growth in the US Market for IV Iron III-1

Regulatory Environment to Affect IV Iron Market in Future III-1

Noteworthy Trend in IV Iron Utilization in the US III-1

Competitive Scenario III-2

Table 7: US IV Iron Therapy Replacement Market (2009):

Percentage Breakdown of Volume Sales by Products for

Venofer, Ferrlecit, INFeD, Dexferrum and Feraheme (includes

corresponding Graph/Chart) III-2

Table 8: US IV Iron Therapy Replacement Market (2008):

Percentage Breakdown of Value Sales by Products for

Venofer, Ferrlecit, INFeD, and Dexferrum (includes

corresponding Graph/Chart) III-2

Product Launches/Approvals III-3

Strategic Corporate Developments III-4

Select Players III-5

B.Market Analytics III-7

Table 9: US Recent Past, Current and Future Analysis for

Intravenous (IV) Iron Drugs with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) III-7

Table 10: US Historic Review for Intravenous (IV) Iron Drugs

with Annual Sales Figures in US$ Million for Years 2001

through 2006 (includes corresponding Graph/Chart) III-8

2. EUROPE III-9

A.Market Analysis III-9

Outlook III-9

Product Launches/ Approvals III-9

Strategic Corporate Developments III-9

Select Players III-11

B.Market Analytics III-13

Table 11: European Recent Past, Current and Future Analysis

for Intravenous (IV) Iron Drugs with Annual Sales Figures in

US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-13

Table 12: European Historic Review for Intravenous (IV) Iron

Drugs with Annual Sales Figures in US$ Million for Years

2001 through 2006 (includes corresponding Graph/Chart) III-13

3. REST OF WORLD III-14

A.Market Analysis III-14

Outlook III-14

Strategic Corporate Developments III-14

B.Market Analytics III-15

Table 13: Rest of World Recent Past, Current and Future

Analysis for Intravenous (IV) Iron Drugs with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-15

Table 14: Rest of World Historic Review for Intravenous (IV)

Iron Drugs with Annual Sales Figures in US$ Million for

Years 2001 through 2006 (includes corresponding Graph/Chart) III-15

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 18 (including Divisions/Subsidiaries - 24)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 9

Japan 1

Europe 8

France 1

Germany 2

The United Kingdom 2

Rest of Europe 3

Asia-Pacific (Excluding Japan) 6

------------------------------------------

To order this report:

Drug Delivery Technology Industry: Global Intravenous (IV) Iron Drugs Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Hearing Aid Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017
2. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
3. Reportlinker Adds Renal Dialysis Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
4. Reportlinker Adds Cardiovascular Monitoring and Diagnostic Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
5. Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
6. VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia
7. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
8. Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference
9. Unilife to Present at the 2011 Jefferies Global Healthcare Conference in New York City
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Derycz Scientific Hires AstraZeneca Executive to Drive Global Sales Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
Breaking Medicine Technology:
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
(Date:6/24/2016)... ... 2016 , ... Advanced Plastic Surgery Institute ( http://www.advancedplasticsurgeryinstitute.com ), ... official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns the practice, ... says the decision to support the pageant in an official capacity is a ...
(Date:6/24/2016)... ... 2016 , ... To succeed under value-based payments, healthcare providers ... how to move forward, given the need to sustain current operations. PYA has ... an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers want ...
Breaking Medicine News(10 mins):